Centuri’s Backlog Booming, Debt Looms on Stock Outlook
Centuri Holdings ends 2025 with a booming backlog and falling debt, yet investors face a high bar to justify lofty va...
What Is Glide Path In Target Date Funds
Glide path describes how a target date fund changes its asset mix as the target year approaches, balancing risk and growth for your retirement.
25,488 articles
Oracle ORCL 2026 Earnings: What to Expect for Investors
As Oracle prepares to report its Q4 2026 results, investors are weighing the cloud growth story, AI bets, and margin ...
Analysts Love AppLovin Stock, Yet Markets Stay Cautious
AppLovin posted stronger-than-expected Q4 results with robust margins and a strategic pivot to e-commerce ads, while ...
Tetra Technologies After Insider Buy: Is It a Buy?
A single insider purchase can spark questions about a stock, but it isn’t a sure shot signal. This article digs into ...
Crinetics Director Sells 5,000 Shares: Key Takeaways
A Crinetics director sells 5,000 shares as the stock dips. This guide breaks down what insider moves really mean for ...
Best Ways to Accumulate Credit Card Points: Smart Strategies
Looking to maximize every purchase? This guide reveals the best ways to accumulate credit card points—from signup bon...
Saved Million Retirement Enough? Couple Weighs Early Exit
A financially secure couple with a three million dollar nest egg wonders if their plan can support an early retiremen...
Vanguard’s Carries Amazon Tesla in Focus ETF Risk
VCR is down about 9% year-to-date, but nearly 40% of its holdings sit in Amazon and Tesla, reshaping the fund’s risk ...
280% YTD, Will AMD’s Rally Continue in 2026?
AMD has ridden a steep year-to-date surge powered by AI and cloud demand. Analysts warn the rally faces hurdles, but ...
Where Will Rare Earth Stocks Head: USA Rare Earth Outlook
Narrowing the lens on rare earths reveals how policy shifts, EV demand, and new mines could shape USA Rare Earth's st...
Three Biotechs That Takeover: Top 2026 M&A Targets
As large pharma hunts for GLP-1 and cardiovascular assets, three biotechs stand out as hot takeover targets. This rep...
CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status